She was the first, but she is no longer the only one. In 2015 Liz Parrish, founder and CEO of BioViva Science, received two experimental gene therapies that were being developed by her own company, making her the “patient zero” who has demonstrated the success of telomerase activation in human beings. According to information provided by the company itself, a few months ago more people began to participate in the same process.

 

These treatments, which BioViva Science and its partner company Integrated Health Systems (IHS) are offering in the city of Monterrey (Mexico), will be the focus of part of the presentation to be offered by Liz Parrish on 15 de November in Valencia on the occasion of the Longevity World Forum, the international congress on healthy aging and life expectancy which has again chosen this city as the venue for its second edition.

 

During her presentation Liz Parrish will also report on the AAV (Adeno Associated Virus) method, which integrates pre-programmed DNA fragments in the nuclear DNA to stimulate the production of certain proteins that are no longer produced with aging and which are necessary to delay the appearance of chronic diseases associated with old age. Furthermore, she will talk about research being conducted by BioViva Science together with Rutgers University of New Jersey (USA) to design a “rejuvenating vaccine” which does not involve genome editing and which causes a minimal immune response.

 

Liz Parrish joins the list of authoritative voices on longevity who will meet on 13, 14 and 15 November at the Longevity World Forum. Participants will include, for example, María Blasco, director of the Spanish National Cancer Research Centre (CNIO), Rafael de Cabo, chief of the Translational Gerontology Branch of the National Institute on Aging in Baltimore (USA); Maria Entraigues Abramson, Global Outreach Coordinator of SENS Research Foundation (USA); Avan Sayer, director of the Newcastle Institute for Ageing (United Kingdom); and Álvaro Pascual-Leone, professor of Neurology at the Harvard Medical School (USA); among others.

 

Thus, the second edition of the Longevity World Forum will focus on scientific innovation, explaining the latest research currently underway in the field of longevity, the guidelines recently proven to be ideal to achieve healthy aging, and the social and economic effects inherent to growing life expectancy.